Expert Guidance on the Evolving Therapeutic Landscape for HER2-Positive Early-Stage Breast Cancer

Read this expert-authored online activity and download the associated slides to learn more about optimal management of patients with HER2-positive early breast cancer.
Lee Schwartzberg, MD, FACP

Text Module

Gain expert perspective on emerging treatments for HER2-positive early breast cancer, including neoadjuvant and adjuvant therapy, strategies for high-risk patients, and managing adverse events.

Lee Schwartzberg, MD, FACP Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: August 10, 2020 Expired: August 9, 2021

Downloadable Slideset

Download this slideset from Lee Schwartzberg, MD, FACP to review key data on optimal treatment for HER2-positive early breast cancer, including neoadjuvant and adjuvant therapy.

Lee Schwartzberg, MD, FACP Released: August 10, 2020
Provided by Clinical Care Options, LLC.

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
Puma Biotechnology

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue